Oxford Science Enterprises

What an excellent turnout at Wednesday's investor event! We were thrilled to welcome, alongside Cambridge Innovation Capital and Northern Gritstone, over 300 institutional investors, including Mansion House signatories, pension funds, global venture investors, asset managers, and UK policymakers.   The energy in the room was palpable, as we showcased groundbreaking innovations from UK university spin-outs and explored the vast investment potential in Life Sciences, Health Tech, and Deep Tech.    A big thank you to all of our sponsors, speakers, panellists, and attendees for making it a success!   Here’s to driving the future of UK innovation together ⚡ British Business Bank, City of London Corporation, Innovate UK, Global Corporate Venturing, PwC, Taylor Wessing UK   Sir Nicholas Lyons, Nicola Blackwood, Louis Taylor, Scott James O'Brien, Edward Bussey, Heather Roxborough, Ben Luckett, Optalysys, adsilico Limited, Sheena Macpherson, Nick New, Vaysh Kewada, Salience Labs, Allan Bradley, T-Therapeutics Ltd, Aidan Crawley, Amber Therapeutics, Ros Deegan, OMass Therapeutics, Andrew Williamson, Duncan Johnson, Anne Horgan (nee Nguyen), Marion Bernard, Anna Dickinson #UKspinouts, #Innovation, #healthtech #LifeSciences #DeepTech

Today we're excited to announce that we're co-hosting our first combined investor event alongside Cambridge Innovation Capital and Northern Gritstone! This event showcases some of the most groundbreaking innovations from UK university spin-outs, and we're thrilled to highlight the incredible investment opportunities within the UK's thriving innovation ecosystem. With insightful presentations from leading figures such as Lord Jim O’Neil, Sir Nicholas Lyons, Baroness Nicola Blackwood, Louis Taylor of British Business Bank, Scott James O'Brien of Innovate UK and Ben Luckett of Aviva, as well as pitches from visionary founders in Life Sciences, Health Tech, and Deep Tech. With special thanks to our sponsors City of London Corporation, British Business Bank, Innovate UK, Global Corporate Venturing, Taylor Wessing, PwC, and to all of our speakers Duncan Johnson, Andrew Williamson, Heather Roxborough, Aidan Crawley of Amber Therapeutics, Sheena Macpherson of adsilico Limited, Marion Bernard, Vaysh Kewada of Salience Labs, Nick New of Optalysys, Anne Horgan (nee Nguyen), Allan Bradley of T-Therapeutics Ltd, Ros Deegan of OMass Therapeutics and Edward Bussey. Let’s invest in tomorrow’s global success stories, today. #UKspinouts #UKInnovation #InvestingInTheFuture #UniversitySpinouts #LifeSciences #DeepTech #entrepreneurship #impact

Our CEO Edward Bussey recently sat down with Quad, Oxford's Alumni Magazine, to reflect on his journey since joining OSE one year ago and share his vision for the future. In the interview, Ed discusses his perspective on the unique opportunity that comes with leading OSE, busts common myths about what we do, and highlights the company's critical role in shaping the next generation of transformational businesses. His vision for the future of innovation in the UK calls for the unlocking of more scale-up capital (via Mansion House Compact), greater collaboration between industry and government, and moving at 10x the speed to maximise the crucial role that spinout companies have in supporting the country's economic growth and productivity. 🔗 Read the full interview, written by Richard Lofthouse here- https://lnkd.in/efmwxbDG #Leadership #Innovation #OxfordAlumni #OxfordInnovation

📽️ #MeetThePortfolio - Genomics plc  🧬Sir Peter Donnelly, CEO of Genomics plc, is leading a groundbreaking effort to transform disease prevention through advanced genetic testing. The company’s platform is designed to detect and eliminate the genetic risk of common diseases before they become serious health issues. Earlier this year, Genomics plc raised £35 million to accelerate the adoption of their cutting-edge testing technology, which uses genotyping to identify high-risk individuals who are often "invisible to the system." Their work holds immense potential for shaping the future of personalised medicine and disease prevention. #HealthTech #Innovation

🌟 We’re thrilled to share that OSE is recognised as a top investor in women-powered businesses, by the annual J.P. Morgan Private Bank's Women-Powered Business Report produced in partnership with Beauhurst. Women-owned and women-led businesses are critical to the success of our global economies, contributing over £116bn in annual turnover. At OSE, we're proud to work with incredible female founders across our life sciences, health tech, and deep tech portfolio companies. Pictured: Caroline Cake, Co-Founder & CEO of Neu Health, Vaysh Kewada, Co-Founder & CEO of Salience and Ros Deegan, CEO of OMass. Read the full report: https://lnkd.in/eiN8wQKY #FemaleEntrepreneurship #DiversityinTech #innovation

#MeetThePortfolio - Amber Therapeutics 🎥 Aidan Crawley shares his experience and journey from an OSE Entrepreneur in Residence to co-founder and CEO of Amber Therapeutics. 🧠 Aidan worked with leading scientists from the University of Oxford to create a company developing a groundbreaking new approach for the treatment of mixed urinary incontinence – a debilitating medical condition affecting millions of women globally. Amber recently raised one of the largest funding rounds ($100 million) for a med tech company in Europe. #healthtech #innovation

🚀#PortfolioNews Congratulations to Dr Gabriele Pupo and the entire FluoRok team on raising £7.7m to transform the safety and sustainability of fluorochemical production. The funding will support team growth and expanded production facilities for the initial supply of fluorinating reagents and lithium hexafluorophosphate (LiPF6), a key component of lithium-ion batteries. The round was led by BGF alongside Green Generation Fund, Volta Energy Technologies, and current investors, including OSE. This investment will help FluoRok scale its technology, bypassing hazardous antiquated methods, to deliver a more sustainable and cost-effective approach to fluorochemical manufacturing. 🌍⚡ Full announcement: https://lnkd.in/gmVNUSeZ #biotech #techfunding #innovation

🌍 This week OSE's Health Tech team have been at LSI Europe, one of the world’s most influential medtech conferences: Yesterday saw a great session on the landmark $100m Series A fundraise by our portfolio company Amber Therapeutics with Amber co-founder and CEO Aidan Crawley, OSE's Liliane Chamas, PhD, as well as Murielle Thinard McLane and Caroline Gaynor. OSE's Tatiana Lobanov-Rostovsky also spoke on a panel alongside several health tech ventures, discussing the top tips and potential pitfalls of securing downstream investment. Great to have participated this week and help drive important conversations on the future of medtech investment and innovation! #MedTech #Innovation #LSIEurope

🚀 Exciting news from our portfolio company ONI as they move into Lipid Nanoparticle (LNP) research! LNPs are changing how therapies including mRNA vaccines, gene therapy and personalised medicine are delivered by precisely targeting and protecting fragile molecules. ONI’s advanced Nanoimager technology gives detailed insights into how LNPs behave, helping improve the efficiency and stability of drug delivery. We’re proud to support ONI in advancing healthtech innovation. #OSE #healthtech #innovation

🏆 Oxford Science Enterprises has been selected as the Top Recognised VC in the British Private Equity & Venture Capital Association (BVCA)'s 2024 Excellence in ESG Awards!   Our Responsible Investment and ESG Manager Emily Matthews received the award which recognises OSE’s commitment to ESG.    Environmental, social, and governance issues are fundamental to successfully building transformational businesses. At OSE, we recognise that ESG criteria must be integrated into our own operations, our investment process, and across our portfolio.    As we continue our sustainability journey, we look forward to further collaborating with our team, portfolio, and the wider industry to support the next generation of companies to integrate ESG into their businesses from day one.   #BVCA #ExcellenceinESG